Seminars in Oncology
Volume 33 , Pages 2-7 , April 2006

The Use of Early Adjuvant Aromatase Inhibitor Therapy: Contributions From the BIG 1-98 Letrozole Trial

  • John F. Forbes

      Affiliations

    • Dr Forbes has served as a member of an advisory board for Eli Lilly, Astra-Zeneca, and Novartis.
    • Corresponding Author InformationAddress correspondence and reprint requests to John F. Forbes, MD, FRACS, ANZ Breast Cancer Trials Group-University of Newcastle, Department of Surgical Oncology, Newcastle Mater Hospital, Edith St, Newcastle, NSW, 2298, Australia.

References 

  1. Winer EP , Hudis C , Burstein HJ , et al.   American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer (Status report 2004) . J Clin Oncol . 2005;23:619–629
  2. Goldhirsch A , Glick JH , Gelber RD , et al.   Meeting highlights (International expert consensus on the primary therapy of early breast cancer 2005) . Ann Oncol . 2005;16:1569–1583
  3. Bernardi A , Zamagni C , Di Fabio F , et al.   Randomized comparative study on estrogen suppression induced by 3 different aromatase inhibitors in postmenopausal women with advanced breast cancer . (abstr 217) Proc Am Soc Clin Oncol . 2002;21(suppl):55A
  4. Geisler J , Haynes B , Anker G , et al.   Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study . J Clin Oncol . 2002;20:751–757
  5. Ellis MJ , Coop A , Singh B , et al.   Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer (Evidence from a phase III randomized trial) . J Clin Oncol . 2001;19:3808–3816
  6. Eiermann W , Paepke S , Appfelstaedt J , et al.   Preoperative treatment of postmenopausal breast cancer patients with letrozole (A randomized double-blind multicenter study) . Ann Oncol . 2001;12:1527–1532
  7. Mouridsen H , Gershanovich M , Sun Y , et al.   Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer (Results of a phase III study of the International Letrozole Breast Cancer Group) . J Clin Oncol . 2001;19:2596–2606
  8. Mouridsen H , Gershanovich M , Sun Y , et al.   Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women (Analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group) . J Clin Oncol . 2003;21:2101–2109
  9. Rose C . A comparison of the efficacy of aromatase inhibitors in second-line treatment of metastatic breast cancer . Am J Clin Oncol . 2003;26:S9–S16
  10. Goss PE , Ingle JN , Martino S , et al.   A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer . N Engl J Med . 2003;349:1793–1802
  11. Baum M , Budzar AU , Cuzick J , et al.  ATAC Trialists’ Group   Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer (First results of the ATAC randomised trial) . Lancet . 2002;359:2131–2139
  12. Baum M , Buzdar A , Cuzick J , et al.   Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer (Results of the ATAC trial efficacy and safety analyses) . Cancer . 2003;98:1802–1810
  13. Howell A , Cuzick J , Baum M , et al.   Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer . Lancet . 2005;365:60–62
  14. Buzdar A , Macahilig C . How rapidly do oncologists respond to clinical trial data? . Oncologist . 2005;10:15–21
  15. Thürlimann B , Keshaviah A , Coates AS , et al.  Breast International Group (BIG) 1-98 Collaborative Group   A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer . N Engl J Med . 2005;353:2747–2757
  16. Mincey BA , Perez EA . Aromastase inhibitors and bone health. ASCO Educational Book . In: Alexandria, VA: American Society of Clinical Oncology; 2005; 27-24
  17. Harper-Wynne C , Ross G , Sacks N , et al.   Effects of the aromatase inhibitor letrozole on normal breast epithelial cell proliferation and metabolic indices in postmenopausal women (A pilot study of breast cancer prevention) . Cancer Epidemiol Biomarkers Prev . 2002;11:614–621
  18. Heshmati HM , Khosla S , Robins SP , et al.   Role of low levels of endogenous estrogen in regulation of bone resorption in late postmenopausal women . J Bone Miner Res . 2002;17:172–178
  19. Wasan KM , Goss PE , Pritchard PH , et al.   The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L) . Ann Oncol . 2005;16:707–715
  20. Goss PE , Ingle JN , Martino S , et al.   Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer (Updated findings from NCIC CTG MA.17) . J Natl Cancer Inst . 2005;97:1262–1271
  21. Rutqvist LE , Mattsson A  The Stockholm Breast Cancer Study Group . Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen . J Natl Cancer Inst . 1993;85:1398–1406
  22. McDonald CC , Alexander FE , Whyte BW , et al.  The Scottish Cancer Trials Breast Group   Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial . BMJ . 1995;311:977–980
  23. Costantino JP , Kuller LH , Ives DG , et al.   Coronary heart disease mortality and adjuvant tamoxifen therapy . J Natl Cancer Inst . 1997;89:776–782
  24. Bradbury BD , Lash TL , Kaye JA , et al.   Tamoxifen-treated breast carcinoma patients and the risk of acute myocardial infarction and newly-diagnosed angina . Cancer . 2005;103:1114–1121
  25. Braithwaite RS , Chlebowski RT , Lau J , et al.   Meta-analysis of vascular and neoplastic events associated with tamoxifen . J Gen Intern Med . 2003;18:937–947
  26. Reis SE , Costantino JP , Wickerham DL , et al.  NSAPB Prevention Trial Investigators   Cardiovascular effects of tamoxifen in women with and without heart disease (Breast cancer prevention trials) . J Natl Cancer Inst . 2001;93:16–21
  27. Fisher B , Costantino JP , Wickerham DL , et al.   Tamoxifen for prevention of breast cancer (Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study) . J Natl Cancer Inst . 1998;90:1371–1388
  28. Fisher B , Dignam J , Bryant J , et al.   Five versus more than five years of tamoxifen for lymph node-negative breast cancer (updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial) . J Natl Cancer Inst . 2001;93:684–690
  29. Coombes RC , Hall E , Gibson LJ , et al.   A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer . N Engl J Med . 2004;350:1081–1092
  30. Kannel WB . Hazards, risks, and threats of heart disease from the early stages to symptomatic coronary heart disease and cardiac failure . Cardiovasc Drugs Ther . 1997;11(suppl 1):199–212
  31. Kannel WB , Wilson PW , D’Agostino RB , et al.   Sudden coronary death in women . Am Heart J . 1998;136:205–212
  32. Sourander L , Rajala T , Raiha I , et al.   Cardiovascular and cancer morbidity and mortality and sudden cardiac death in postmenopausal women on oestrogen replacement therapy (ERT) . [erratum in: Lancet 353:330, 1999] Lancet . 1998;352:1965–1969
  33. ATAC Trialists Group, Royal Marsden Hospital, London, United Kingdom Dowsett M . Analysis of time to recurrence in the ATAC (Arimidex, tamoxifen, alone or in combination) trial according to estrogen receptor and progesterone receptor status . (abstr 4) Breast Cancer Res Treat . 2003;82(suppl):S7
  34. Howell A . The ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial in postmenopausal women with early breast cancer–Updated efficacy results based on a median follow-up of 5 years . 2004; Presented at the 24th Annual San Antonio Breast Cancer Symposium, December [Poster 1]
  35. Saphner T , Tormey DC , Gray R . Annual hazard rates of recurrence for breast cancer after primary therapy . J Clin Oncol . 1996;14:2738–2746

PII: S0093-7754(06)00174-6

doi: 10.1053/j.seminoncol.2006.03.026

Seminars in Oncology
Volume 33 , Pages 2-7 , April 2006

Article Tools

* Image Usage & Resolution